Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 2/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25605288 | 0.98 | LMNA (0.36) | LMNASMN1; SMN2L3MBTL1TNIKALDH1A1 | |
| SCHEMBL25605285 | 0.97 | LMNA (0.35) | LMNASMN1; SMN2L3MBTL1TNIKALDH1A1 | |
| SCHEMBL18102197 | 0.95 | TNIK (0.34) | LMNASMN1; SMN2L3MBTL1TNIKALDH1A1 | |
| SCHEMBL25716497 | 0.95 | TNIK (0.37) | LMNASMN1; SMN2L3MBTL1TNIKALDH1A1 | |
| SCHEMBL3957979 | 0.94 | TNIK (0.34) | LMNASMN1; SMN2L3MBTL1TNIKALDH1A1 | |
| SCHEMBL3956773 | 0.94 | TNIK (0.35) | LMNASMN1; SMN2L3MBTL1TNIKALDH1A1 | |
| SCHEMBL25849353 | 0.93 | TNIK (0.37) | LMNASMN1; SMN2L3MBTL1TNIKALDH1A1 | |
| SCHEMBL3962299 | 0.93 | RAF1 (0.35) | LMNASMN1; SMN2L3MBTL1TNIKALDH1A1 | |
| SCHEMBL1186375 | 0.93 | TNIK (0.33) | LMNASMN1; SMN2L3MBTL1TNIKALDH1A1 | |
| SCHEMBL18099445 | 0.93 | TNIK (0.33) | LMNASMN1; SMN2L3MBTL1TNIKADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078006-B1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL INC (US) | 2018-11-07 | — | — | EP | claimed |
| US-8748634-B2 | Photochromic materials demonstrating improved fade rates | TRANSITIONS OPTICAL, INC. (US) | 2014-06-10 | — | — | US | claimed |
| EP-2078006-A2 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2008054942-A2 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-08 | — | — | WO | claimed |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-01 | — | — | US | claimed |
| EP-4269532-A1 | PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES | Hoya Lens Thailand Ltd. (TH) | 2023-11-01 | — | — | EP | disclosed |
| EP-4270067-A1 | PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND GLASSES | Hoya Lens Thailand Ltd. (TH) | 2023-11-01 | — | — | EP | disclosed |
| US-20230340318-A1 | PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES | HOYA LENS THAILAND LTD. (TH) | 2023-10-26 | — | — | US | disclosed |
| US-20230227717-A1 | PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND SPECTACLES | HOYA LENS THAILAND LTD. (TH) | 2023-07-20 | — | — | US | disclosed |
| EP-2078006-B1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-9006427-B2 | Photochromic materials demonstrating improved fade rates | TRANSITIONS OPTICAL, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006427-B2 | Photochromic materials demonstrating improved fade rates | TRANSITIONS OPTICAL, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8748634-B2 | Photochromic materials demonstrating improved fade rates | TRANSITIONS OPTICAL, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140155598-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155598-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2078006-A2 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008054942-A2 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | PNPO, FLAD1, CRY2 | LMNA 727/4885SMN1; SMN2 1782/4885L3MBTL1 3096/4885 |
| US-20230340318-A1 | PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES | NR2E3, CRY1, RPS10 | LMNA 4515/4885SMN1; SMN2 3937/4885L3MBTL1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.